STI Stock Trade Intelligence
CMB

CAMBIUM BIO LIMITED

Health Care · ASX:CMB
$0.5000
▼ -9.09%
Market cap
$15M
Turnover
$188
Last price
$0.5000
Day change
-9.09%
Announcements
6
Range, past year
Open 0.520 · Low 0.190 · Now 0.500 · High 0.600
Open CMB in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

CMB momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-09-28.
Momentum quality
42/100
Wyckoff phase
Accumulation1d
Trend stage
Emerging
1 Day
-9.1%
1 Week
-3.8%
1 Month
+19.0%
1 Year
-3.8%
RSI
57
Avg daily range
3.2%

CAMBIUM BIO LIMITED scores 42 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.

On the Wyckoff cycle it sits in Accumulation, where it has been for 1 trading day. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.

Against the wider market it is currently outperforming and the institutional accumulation signal reads low.

What stands out
  • Fresh trend age (18 days)
  • RSI in healthy zone (57)
Points to watch
  • Thin liquidity
CMB appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

CMB announcements

Recent price-sensitive releases.
  • 2026-09-16 Cambium Bio Secures A$10.85 Million Funding Package Placement | Issued Capital - Other
  • 2026-08-28 FY26 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-07-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-22 Cambium Bio Raises A$1.0 Million via Placement
  • 2026-04-28 Quarterly Activities/Appendix 4C Cash Flow Report
  • 2026-04-23 FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.